In Vivo CAR Therapy and Targeted Lipid Nanoparticle Delivery Combined in Single Platform as CREATE Medicines and WestGene Biopharma Enter Strategic R&D Collaboration

InnoDexis has published its latest Innovation Intelligence Report covering in vivo cell therapy and targeted drug delivery, analyzing a strategic R&D collaboration spanning autoimmune diseases, solid tumours, and four clinical markets. The report reveals that CREATE Medicines and WestGene Biopharma have entered a collaboration combining CREATE's in vivo immune programming and RetroT RNA gene-writing technology with WestGene's targeted lipid nanoparticle delivery system — creating a platform designed to programme immune cells inside the body without the ex vivo manufacturing process that defines current CAR-T therapy.

Key Findings

More than 60 patients have already been dosed across CREATE Medicines' in vivo CAR clinical programmes prior to the formation of this collaboration. This clinical foundation distinguishes the platform from pre-clinical stage announcements and establishes a base of translational data from which the combined architecture can generate further insights at accelerated pace. The existing patient dosing record materially changes the speed and quality of evidence this collaboration can produce.

The platform integrates two technically distinct capabilities in a single architecture: CREATE's RetroT site-specific RNA gene integration and WestGene's targeted lipid nanoparticle delivery technology. RetroT enables precise, site-specific RNA gene writing, while the targeted lipid nanoparticle system addresses durable expression and precise cellular targeting. The combination of these two functions within one platform represents a technically integrated approach among in vivo cell therapy architectures currently in development.

The collaboration pipeline includes dual-target CD19 x BCMA immune programming — a design that addresses two clinically validated targets within a single in vivo therapeutic approach. CD19 and BCMA are established targets in haematological malignancies and autoimmune disease, and their inclusion in the pipeline signals clinical translation intent toward indication areas with existing regulatory precedent.

Clinical trial execution in China is included in the collaboration structure, spanning four clinical markets. Multi-geography clinical execution generates regulatory-relevant data across different patient populations and regulatory jurisdictions simultaneously, accelerating the pace at which translational evidence can be accumulated relative to single-market programmes. This structural feature of the collaboration has direct implications for the speed of regulatory and commercial validation for the in vivo CAR therapeutic class.

The platform is designed to eliminate the ex vivo cell manufacturing process that currently defines CAR-T therapy logistics. Ex vivo manufacturing requires patient cells to be extracted, engineered outside the body, and reinfused — a process that is complex, costly, and limits access at scale. In vivo immune programming via targeted lipid nanoparticles removes this manufacturing dependency, repositioning cell therapy delivery toward an off-the-shelf model.

Strategic Insight and Trend Analysis

The strategic significance of this collaboration is structural rather than incremental. Current CAR-T therapy operates within a manufacturing paradigm that has constrained access since the first approvals: every patient requires individualised cell extraction, engineering, and reinfusion, creating logistical complexity that limits the populations this therapeutic class can reach. The CREATE-WestGene platform does not improve this process — it removes it.

In vivo immune programming via targeted lipid nanoparticles addresses the root cause of CAR-T access limitations rather than optimising around them. If immune cells can be programmed inside the body with the precision and durability previously only achievable through ex vivo engineering, the manufacturing bottleneck that has defined cell therapy economics and logistics since inception is structurally resolved rather than managed.

The technical integration of RetroT RNA gene-writing with targeted lipid nanoparticle delivery is the mechanism through which this resolution is attempted. RNA gene-writing provides the precision of site-specific integration; targeted nanoparticle delivery provides the cellular specificity required to direct that integration to the correct immune cell populations in vivo. Together they address the two core technical requirements — precision and durability — that ex vivo manufacturing has historically been necessary to satisfy.

The clinical foundation of more than 60 dosed patients further separates this platform from the pre-clinical in vivo cell therapy landscape. Organisations evaluating the in vivo CAR space are no longer assessing theoretical feasibility — they are assessing a platform with active clinical data and a multi-geography execution structure capable of generating regulatory-relevant evidence across multiple markets simultaneously.

Global and Industry Implications

For corporates and R&D teams in biotechnology and pharmaceutical research, the CREATE-WestGene collaboration signals that in vivo immune programming is advancing beyond proof-of-concept toward a clinically active development phase. Organisations with CAR-T programmes should monitor the translational data emerging from this platform, particularly across autoimmune and solid tumour indications where ex vivo manufacturing constraints have historically limited therapeutic reach.

For investors and capital allocators, the collaboration presents a differentiated profile within the cell therapy sector: a platform with an existing clinical dosing record, a technically integrated delivery architecture, dual-target pipeline assets, and multi-geography clinical execution. The combination of clinical validation and structural manufacturing advantage addresses two of the primary risk factors that have historically constrained cell therapy investment at scale.

For policymakers and national innovation bodies, multi-geography clinical execution spanning four markets including China represents an emerging model for accelerating regulatory data generation across jurisdictions simultaneously. This structure has implications for how regulatory frameworks accommodate globally executed clinical programmes for novel therapeutic modalities such as in vivo cell therapy.

InnoDexis Statement

"The integration of in vivo immune programming with targeted lipid nanoparticle delivery addresses the manufacturing bottleneck that has structurally constrained CAR-T access since its inception — moving the therapeutic class from patient-specific production toward a scalable delivery architecture," noted InnoDexis in its latest intelligence report.

Conclusion

In vivo CAR therapy represents one of the most structurally significant shifts in cell therapy development currently visible in the innovation pipeline. As the CREATE-WestGene platform advances through multi-geography clinical execution, the translational data it generates will inform both the scientific and regulatory frameworks for this emerging therapeutic class. InnoDexis will continue to monitor developments in in vivo immune programming, targeted lipid nanoparticle delivery, and the broader transition from ex vivo to in vivo cell therapy architectures. The complete In Vivo Cell Therapy Innovation Intelligence Report is available to InnoDexis subscribers and enterprise clients.

About InnoDexis

InnoDexis is a global Innovation Intelligence platform that tracks, analyzes, and interprets breakthrough innovations, prototypes, and emerging technologies across industries and countries. Its intelligence helps corporates, investors, and policymakers understand the true structure and direction of global innovation. Learn more at innodexis.ai.